<DOC>
	<DOCNO>NCT02040584</DOCNO>
	<brief_summary>Assuming great efficacy prevention acute rejection EVR arm minimisation TAC level , hypothesis present trial introduction EVR combination minimisation TAC ( rTAC ) may offer improved kidney function compare standard therapy TAC-MMF .</brief_summary>
	<brief_title>A Multicentre , Randomised , Open-label , Controlled , 12-month Follow-up Study Assess Impact Renal Function Immunosuppression Regimen Based Tacrolimus Minimisation Association With Everolimus de Novo Liver Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Screening Visit Inclusion Criteria 1 . Recipients age 18 receive first liver transplant cadaver donor . 2 . Patients diagnose HCC must meet Milan radiological criterion time transplant ( 1 nodule ≤5 cm diameter , 23 nodule , &lt; 3 cm diameter ) . 3 . Patients sign informed consent participate study . 4 . Patients medical criterion capable comply study regimen . Screening Visit Exclusion Criteria 1 . Recipients receive multiple transplant solid organ pancreatic islet cell . 2 . Patients previously receive organ tissue transplant . 3 . Patients combine liverkidney transplant . 4 . Recipients lobes segment liver live donor . 5 . A history malignancy organ system previous 3 year accord local protocol ( regardless sign local recurrence metastasis ) , nonmetastasising basal cell carcinoma squamous cell carcinoma ( epidermoid carcinoma ) skin , HCC . 6 . Patients know hypersensitivity drug use study others class , excipients . 7 . Recipients ABOincompatible transplant . 8 . Patients test positive HIV . 9 . Recipients organs donor test positive hepatitis B surface antigen HIV seropositive . 10 . Patients medical surgical condition opinion investigator may significantly alter absorption , distribution , metabolism excretion study medication . 11 . Women childbearing potential ( i.e . woman postmenopausal amenorrhoea 1 year surgically sterile ) plan become pregnant , pregnant and/or breastfeeding , wish use effective contraception , e.g . hormonal contraceptive ( implantation , patch , oral ) doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , contraceptive sponge , cervical cap ) . 12 . Patients take part another clinical trial . Randomisation Visit Inclusion Criteria 1 . Functioning allograft time randomisation . A functioning allograft define : 1. level AST , ALT total bilirubin ≤ 4 time upper limit normal , 2. level alkaline phosphatase GGT ≤ 5 time upper limit normal . 2 . Glomerular filtrate ≥30 mL/min/1.73 m2 ( calculate use MDRD4 equation ) . Randomisation Visit Exclusion Criteria 1 . Patients proteinuria ≥1.0 g/24 hr confirm urine sample ( protein/creatinine ratio ) explain immediate postoperative cause . 2 . Patients severe hypercholesterolaemia ( ≥350 mg/dL ; ≥9 mmol/L ) severe hypertriglyceridaemia ( ≥750 mg/dL ; ≥8.5 mmol/L ) . 3 . Patients platelet count ≤50,000/mm3 . 4 . Patients absolute neutrophil count ≤1,000/mm3 WBC count ≤2,000/mm3 . 5 . Patients take oral medication . 6 . Patients clinically significant systemic infection require active use intravenous antibiotic . 7 . Patients intensive care unit require vital support measure mechanical ventilation , dialysis , vasoactive drug . 8 . Patients require renal replacement therapy 7 day prior randomisation . 9 . Patients episode acute rejection require antibody therapy one episode corticosteroidsensitive acute rejection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>De Novo Liver Transplant Recipients , Tacrolimus Minimisation , Everolimus , Renal Function</keyword>
</DOC>